GSK wins Zantac trial

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

Law · 6d

GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

Benzinga.com · 4d

GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain.

FiercePharma6d

GSK will pony up $2.2B to resolve 80K Zantac cases

The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.

Los Angeles Daily News6d

GSK to settle 80,000 Zantac cases for up to $2.2 billion

GSK’s move doesn’t end litigation around Zantac as other drugmakers are still facing trials, including Boehringer Ingelheim GmbH, which is facing a jury trial in Oakland.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Trending on Bing

Related topics